Author Contributions: Dr Reulen had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Winter, Lancashire, Stiller, Jenney, Skinner, Stevens, Hawkins.
Acquisition of data: Winter, Stiller, Lancashire, Hawkins.
Analysis and interpretation of data: Reulen, Frobisher, Stiller, Skinner, Stevens, Hawkins.
Drafting of the manuscript: Reulen, Frobisher, Stiller, Skinner, Stevens, Hawkins.
Critical revision of the manuscript for important intellectual content: Reulen, Winter, Frobisher, Lancashire, Stiller, Jenney, Skinner, Stevens, Hawkins.
Statistical analysis: Reulen, Winter, Frobisher.
Obtained funding: Hawkins.
Administrative, technical, or material support: Winter, Lancashire.
Study supervision: Winter, Lancashire, Hawkins.
Financial Disclosures: None reported.
Funding/Support: This work was supported by Cancer Research UK and the Kay Kendall Leukaemia Fund. Dr Reulen was supported by a Cancer Research UK Graduate Training Fellowship. The Childhood Cancer Research Group receives funding from the Department of Health and the Scottish Ministers.
Role of the Sponsor: Cancer Research UK, the Kay Kendall Leukaemia Fund, the Department of Health, and the Scottish Ministers had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.
British Childhood Cancer Survivor Study (BCCSS) Steering Group: The following individuals provided study oversight without compensation: Douglas Easton, PhD (chair), University of Cambridge; Michael Hawkins, PhD (secretary), University of Birmingham; Helen Jenkinson, MD, Birmingham's Children's Hospital; Meriel Jenney, MD, Children's Hospital for Wales, Cardiff; Emma Lancashire, PhD, University of Birmingham; Kathryn Pritchard-Jones, MD, Institute of Cancer Research, Surrey; Michael Stevens, MD, University of Bristol; Charles Stiller, Childhood Cancer Research Group, Oxford; Elaine Sugden, MD, Churchill Hospital, Oxford; Andrew Toogood, MD, University Hospital Birmingham; and Hamish Wallace, MD, Royal Hospital for Sick Children, Edinburgh.
Disclaimer: The views expressed in this article are not necessarily those of Cancer Research UK, the Kay Kendall Leukaemia Fund, the Department of Health, or the Scottish Ministers.
Previous Presentation: This study was presented in part at the 10th International Conference of Long-term Complications of Treatment of Children and Adolescents for Cancer; June 6-7, 2008; Niagara-on-the-Lake, Ontario, Canada.
Additional Contributions: The BCCSS benefits from the contributions of the officers, centers, and individual members of the Children's Cancer and Leukemia Group, Childhood Cancer Research Group, and Regional Pediatric Cancer Registries. The BCCSS acknowledges the collaboration of the Office for National Statistics, General Register Office for Scotland, National Health Service Central Registers, regional cancer registries, health authorities, and area health boards for providing general practitioner names and addresses and the general practitioners nationwide who facilitated direct contact with survivors. The BCCSS would not have been possible without the support of our 2 funders, Cancer Research UK and the Kay Kendall Leukaemia Fund, to whom we offer our profound thanks. Cornelia Rebholz, MSc, University of Bern, and Edwin van Wijngaarden, PhD, University of Rochester, provided comments on earlier drafts of the manuscript, without compensation. We thank all BCCSS staff, who have given many years of dedicated work to bring the BCCSS to fruition.